Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by made2laston May 31, 2018 1:57pm

117 Views

Post# 28106786

RE:RE:RE:RE:RE:RE:I still hear this crapola

Hi All;

NMIBC cancer may not be life threatening initially, however, in the USA alone.....

It is estimated that 17,240 deaths (12,520 men and 4,720 women) from this disease will occur this year. Among men, bladder cancer is eighth most common cause of cancer death.

https://www.cancer.net/cancer-types/bladder-cancer/statistics

The best of luck to all longs;

made2last

enriquesuave wrote: I agree macer Macer that NMIBC is not life threatening, but most patients who failed other treatments would definitely want to save their bladders and try out TLD-1433 . I could imagine that the 50-60% of BCG failed cases of those who also failed experimental treatments like Vicinium or others would want to keep their bladders. If one is given the chance to get a very promising treatment which is deemed safe and has a high chance of being effective, I cannot see who wouldn't want to try.

As for GBM, they need to pass safety first with Rutherin, which is why they are preparing the landscape to maximize both safety and efficacy. I already have a patient of mine informed and possibly willing to participate in a GBM PH1 trial.

enriquesuave wrote:

Macer wrote: With bladder cancer the right to try probably would not apply in most cases as the disease is not terminal in the majority of cases because you can simply remove the bladder.

With GBM this is most likely to be an indication for the right to try. I personally would leave Trump out of any healthcare related decisions, I believe he is a bafoon. And we currently have no idea whether or not the IV administation of TLD 1433 looks anything like the instillation method in terms of safety so it really is too early to even talk about right to try with TLD 1433.

Question: If senator Mclean were to opt to try TLD 1433 for GBM and it destroys his cancer but the treatment leaves him an a vegitative state, what would that do to our investment?
You may be hard pressed to find volunteers to complete our study afterwards.

My guess is that Theralse will not make this available until it is stuidied appropriately. There is too much at risk.

I am all for efficiency and getting things done but I also know that whenever we try to effect change in someones body we normally bugger something else up. Speaking from experience :)
Could we get rid of some red tape, sure. But there are regulations and protocols in place for a reason.

Macer